Interestingly, this increase was not uniform across stages but became more pronounced with advancing disease, suggesting that bioactive sclerostin upregulation may be a later rather than an early feature of the ADPKD bone phenotype. This evidence concerns the gene SOST and autosomal dominant polycystic kidney disease.